127. ESMO 2024 - Day 1

The European Society of Medical Oncology Congress has begun, and Michael and Josh are on the ground, bringing you breaking studies and heartbreaks along with some important updates in the science and art of medical oncology. Michael and Josh cover a range of tumour types on day one, a slight deviation from our regular coverage. They look at hepatocellular carcinoma, renal cancers, and breast cancer, an eclectic but exciting mix of cancer types. Michael investigates HCC treatment with iparomlimab and tuvonaralimab with bevacizumab in a first line setting, along with some updated efficacy from the IMbrave050 trial. He finishes off his whirlwind tour of day one summarising some interesting education points in the metastatic colorectal cancer space. Josh looks at Tivozanib-Nivolumab in advanced RCC following immunotherapy, along with another trial where Belzutifan may be another treatment option. He finishes up with HER3-directed therapy! Links to studies discussed in this episode (subscription may be required): Phs II/III DUBHE-H-308 Imbrave050 (HCC) TiNivo-2 Study (mRCC) Litespark 005 (mRCC) Checkmate 8HW (mCRC) Icarus-Breast 01 (mBreast Cancer) For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at [email protected] Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.